Description
In This Episode:
- Jill Feldman, Lung Cancer Patient and Advocate, Co-Founder of EGFR Registers
- Roy Herbst, MD, PhD, Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital
- Richard Pazdur, MD, Director, FDA Oncology Center of Excellence
- Yuri Rukazenkov, MD, PhD, AstraZeneca, Global Clinical Lead, Oncology
- Harpreet Singh, MD, Medical Officer, FDA
| Name | Financial Relationships | Disclosure Type | Role |
| J. Feldman | No Relationships | Speaker | |
| R. Herbst | AbbVie, ARMO, AstraZeneca, Biodesix, Bolt Biotherapeutics, BMS, Candel, Cybrexa, eFFECTOR, Lilly, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat, I-Mab, Immunocore, Infinity, Junshi, Loxo, Merck, Mirati, Nektar, Neon, NextCure, Novartis, Oncternal, Pfizer, Ribbon, Sanofi, Seattle Genetics, Shire, Spectrum, STCube, Symphogen, Takeda, Tesaro, Tocagen, WindMIL, Xencor | Advisor/Board Member; Consultant/Independent Contractor; Grants/Research Support Recipient | Speaker |
| R. Pazdur | No Relationships |
|
Program Committee, Speaker |
| Y. Rukazenkov | AstraZeneca |
Full-time/part-time Employee |
Speaker |
| H. Singh | No Relationships |
|
Speaker |
FDA staff involved in the development and review of this activity have disclosed no relevant financial relationships.
AACR staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Questions About CE?
Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.
OSIMERTINIB PRESCRIBING INFORMATION